Exelixis, Inc. $EXEL Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 44.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 913,802 shares of the biotechnology company’s stock after buying an additional 279,958 shares during the period. Janus Henderson Group PLC’s holdings in Exelixis were worth $39,199,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Motiv8 Investments LLC acquired a new position in shares of Exelixis in the fourth quarter worth about $26,000. Cassaday & Co Wealth Management LLC purchased a new position in Exelixis in the first quarter valued at about $27,000. Acumen Wealth Advisors LLC acquired a new stake in Exelixis during the 4th quarter valued at approximately $29,000. Activest Wealth Management acquired a new stake in Exelixis during the 4th quarter valued at approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 773 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Stifel Nicolaus upped their target price on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Citigroup restated a “market outperform” rating on shares of Exelixis in a research note on Wednesday, July 22nd. Citizens Jmp upped their price target on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Wednesday, June 24th. Finally, Truist Financial increased their price objective on shares of Exelixis from $54.00 to $56.00 and gave the company a “hold” rating in a research note on Tuesday, July 7th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $49.29.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares in the company, valued at $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher J. Senner sold 34,901 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the sale, the chief financial officer directly owned 952,317 shares in the company, valued at $47,615,850. This trade represents a 3.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 219,170 shares of company stock valued at $10,620,641 over the last quarter. Insiders own 2.60% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL opened at $53.03 on Monday. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 1.53 and a beta of 0.42. The stock has a 50 day moving average of $53.73 and a 200-day moving average of $47.61. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $57.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.55 EPS. On average, sell-side analysts predict that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.